Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial-Reference-Cited by-同舟云学术

Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial

Published:2018-07 Issue:7 Volume:19 Page:987-998
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

von Minckwitz Gunter,Colleoni Marco,Kolberg Hans-Christian,Morales Serafin,Santi Patricia,Tomasevic Zorica,Zhang Nan,Hanes Vladimir

Publisher

Elsevier BV

Subject

Oncology

Reference17 articles.

1. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Aebi;Ann Oncol,2010

2. Locally recurrent or metastatic breast cancer; ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Cardoso;Ann Oncol,2010

3. Mechanism of action of trastuzumab and scientific update;Baselga;Semin Oncol,2001

4. Developing the totality of evidence for biosimilars: regulatory considerations and building confidence for the healthcare community;Markus;BioDrugs,2017

5. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial;Stebbing;Lancet Oncol,2017

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Define Critical Parameters of Trastuzumab-Mediated ADCC Assays via Assay Optimization Processes, Focusing on the Impact of Cryopreserved Effector Cells on Assay Performance;Cancers;2024-06-27

2. Vergleich von Trastuzumab-Biosimilar ABP 980 mit Referenz-Trastuzumab bei der neoadjuvanten Therapie von HER2-positivem Brustkrebs – Analyse eines großen universitären Brustkrebszentrums;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2024-05-23

3. Survey of Data Package and Sample Size of Comparative Clinical Studies for Biosimilar Developments from PMDA Assessments;Pharmaceutical Medicine;2024-04-29

4. Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union;Future Oncology;2024-04

5. Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer;Current Oncology;2024-03-21